GlaxoSmithKline Pharmaceuticals Ltd (GSK) on Friday announced its financial results for the third quarter ended December 31, 2024. According to the company’s exchange filing, it demonstrates strong growth and sustained profitability.
The company reported a 18 percent increase in revenue from operations, reaching Rs.946 crores while achieving a Profit After Tax (PAT) of Rs. 229 crores. The company reported a surge of 402.80 per cent in profit in comparison to Rs 45.72 crore recorded during the corresponding quarter of FY24. The quarter saw strong performance across key product portfolios.
Flagship brands within the general medicines portfolio including Augmentin, Ceftum, and T-bact strengthened their market positions with share gains. The company’s innovative Respiratory portfolio, led by Nucala and Trelegy, achieved robust growth, further expanding patient access across India.
In the vaccines segment, GSK maintained its leadership in the self-pay private market for Paediatric vaccines. The adult vaccines division continues to gain momentum with Shingrix (Herpes Zoster Vaccine – recombinant, adjuvanted), as the company spearheads the expansion of adult immunisation in India.
“Our strong third-quarter results reflect our unwavering commitment to deliver innovative healthcare solutions to patients across India. By focusing on core brands and accelerating digital transformation through innovative go-to-market strategies, we continue to strengthen our market presence while ensuring broader access to our medicines and vaccines,” Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals Limited, said.
